Wall Street analysts are raising price targets on Edwards Lifesciences, citing a renewed growth cycle driven by TAVR expansion and a strong product pipeline, positioning the medical device maker as a favored pick.
Pharmaceutical leader Eli Lilly will build a new manufacturing facility in Lehigh County, marking the largest life sciences investment in Pennsylvania history and bolstering U.S. production of next-generation weight-loss drugs.
Shares of Ethos Technologies have slumped 10.7% year-to-date, trading around $15.05. A detailed valuation analysis reveals a stark contradiction: while a discounted cash flow model suggests massive undervaluation, its price-to-earnings ratio paints a picture of overvaluation. This divergence highlights the critical debate among investors about the insurer's true worth and future trajectory.
Veeva Systems' stock has faced recent pressure, declining over 11% in the past year. A deep dive into its valuation reveals a stark contrast: a discounted cash flow model suggests significant upside, while its premium P/E ratio tells a more cautious tale. We examine the numbers and what they mean for investors eyeing the life sciences cloud leader.
Cogent Biosciences secures FDA Breakthrough Therapy Designation and enters the Real-Time Oncology Review program for its lead drug candidate bezuclastinib in gastrointestinal stromal tumors (GIST), marking significant regulatory momentum for the biotech firm.
Finnish technology leader Valmet introduces a new line of bio-based press roll covers, backed by specific lifecycle assessment data, to help paper manufacturers reduce fossil resource dependence and track emissions.
IDEAYA Biosciences shares have retreated from recent highs, presenting investors with a dilemma. While long-term performance remains strong, its premium valuation and significant net losses raise questions about whether the current price already reflects its promising pipeline.
Cogent Biosciences secures a key FDA Breakthrough Therapy Designation for its bezuclastinib-sunitinib combination in advanced GIST, following promising Phase 3 data that showed a halving of disease progression risk.
As artificial intelligence reshapes the competitive landscape, tech leaders face a stark choice: disrupt their own profitable core businesses or risk being left behind. New financial results from Microsoft, Meta, and Tesla reveal the high-stakes strategies—and market reactions—defining this pivotal moment.
A new report reveals a staggering 67% of purchased sales software features go unused, spotlighting a critical disconnect between tech spending and revenue impact. As IT budgets swell, C-suite leaders are urged to shift from measuring adoption to calculating true dollar-for-dollar returns.
SoFi Technologies capped off a transformative 2025 with its first billion-dollar revenue quarter, fueled by explosive member growth and a strategic pivot toward fee-based services. As the digital finance leader sets ambitious targets for 2026, analysts are weighing its 'one-stop-shop' model against an evolving economic landscape.
LifeSci Capital reaffirms its Buy rating on Olema Pharmaceuticals (OLMA) and raises its price target to $45, following bullish analyst sentiment on the company's lead drug candidate, Palazestrant, for ER+/HER2- breast cancer.
UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.
Fortive Corporation's shares have retreated over 5% in the past month, prompting investors to re-examine the industrial technology conglomerate's fundamentals. With a renewed focus on its recurring revenue streams and a fair value estimate suggesting upside, analysts are divided on whether the pullback presents a buying opportunity or reflects deeper sector headwinds.
As a profitable outlier in a battered sector, Ethos Technologies' successful IPO marks a pivotal test for investor appetite in 2026's tech listings, even as its debut valuation reflects a more sober market reality.
Southeast Asian super app Grab Holdings has appointed Laura Franco to its board, succeeding the retiring Ng Shin Ein. The move signals a governance refresh aimed at steering the company's aggressive expansion into on-demand grocery, financial technology, and next-generation mobility partnerships.
A recent anniversary event for 'Silicon Alley' highlighted how New York's technology sector has evolved from a concentrated downtown community into a vast, decentralized force spanning finance, AI, and e-commerce.
After a prolonged correction, Brent crude oil is showing signs of a potential trend reversal, with a forming double bottom pattern pointing toward a technical target near $95 per barrel. The shift comes amid a tightening physical market and simmering geopolitical risks.
Investment firm Giverny Capital Asset Management reduced its stake in industrial manufacturer AMETEK in Q4 2025, highlighting a disciplined approach to valuation as markets remain captivated by AI narratives. The firm's portfolio underperformed major indices, pressured by its underweight stance in mega-cap technology.
Schweiter Technologies (SWTQ) has seen significant price swings on the SIX Swiss Exchange. With its current valuation trading well above industry peers, we examine whether the stock's optimistic growth prospects justify the premium or if investors should wait for a better entry point.
